Friday, 15 Feb 2019

You are here

ACR Says the New AHCA is Insufficient for Arthritis Patients

Dr. Sharad Lakhanpal, MBBS, MD, President of the American College of Rheumatology (ACR) has issued a press release condeming the insufficiencies of the newly proposed American Health Care Act (AHCA).

The ACR has studied the AHCAA and are encouraged by no exclusions for pre-existing illness, continued limits on patient copayments, caps on out-of-pocket costs, coverage for children on a parent’s insurance until age 26, and a ban on lifetime limits.

The ACR's focus is to ensure Americans have continued access to rheumatology care that lowers long-term costs and helps patients manage pain, avoid long-term disability, remain active in the workforce, and preserve their quality of life. 

Dr. Lakhanpal believes this legislation will hurt patients and rheumatology care.  Objections include:

  • proposed tax credits based on age rather than income
  • allowances for insurers to impose a 12 month 30% premium increase when there is a lapse in coverage >63 days.
  • non-recognition of ACR’s recommendations to minimize the administrative burden on doctors and to repeal the Independent Payment Advisory Board (IPAB).

“We look forward to working with Congressional leaders and the Administration to address these concerns and will continue to provide input on proposed legislation to ensure continued access to vital rheumatology healthcare services,” says Dr. Lakhanpal.

 

 

- See more at: http://www.rheumatology.org/About-Us/Newsroom/Press-Releases/ID/798/ACR-...

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Difference in Oral or IV Antibiotics for Bone & Joint Infections

Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.

There is considerable discussion whether complex bone and joint infections must be managed with prolonged intravenous antibiotics or if oral antibiotic therapy may suffice. 

2019: the Year of Price Hikes

In 2019 there have been numerous reports of higher drug pricing for many drugs.  Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.

Reuters reports that in the United States, the pricing on more than 250 prescription drugs have gone up.

Does Methotrexate Work in Giant Cell Arteritis?

There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use. While well done clinical trials have shown no certain efficacy, data suggesting MTX benefits comes from small trials, anecdotes and clinical experience. 

Price of Drug Promotion Skyrockets

JAMA reports that health care advertising costs in the U.S. have almost doubled over the past two decades, surging from $17.7 billion in 1997 to at least $29.9 billion in 2016. (Citation source: https://buff.ly/2Rk8a9Q)

2018 Rheumatology Year In Review

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likely change their standards and practice in the future, if not 2019.